


# FY 2025 Highlights

"In 2025, Ipsen delivered strong sales and profit growth and continued to execute across all three TAs with a notable performance from Iqirvo."




**David Loew**  
Chief Executive Officer



## Geographic Breakdown

Total sales by region: 2025




**North America**  
**35%**  
of total sales

**Europe**  
**40%**  
of total sales

**RoW**  
**25%**  
of total sales

In this map, Europe is defined as the E.U., the U.K., Iceland, Liechtenstein, Norway, and Switzerland.

### Oncology +4.1%



### Rare Disease +102.5%



### Neuroscience +9.7%



## 2025 Regulatory Highlights

**Tovorafenib:** EMA regulatory submission

**Cabometyx®:** EU approval in NETs

**IPN10200:** Proof-of-concept data readout in aesthetics

## 2026 Guidance<sup>2</sup>

**Total sales growth:** >13.0% at CER<sup>1</sup>

**Core operating margin:** >35.0% of total sales